Clinical Trial Update: HL2351 CAPS Phase II Study [Phase 2]

View source ↗

Summary

Phase II study of HL2351 for Cryopyrin-associated periodic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndromes

Drugs mentioned

• HL2351

Snippet

Sponsor: Handok Inc. | Conditions: Cryopyrin-Associated Periodic Syndromes (CAPS) | Phase 2 | Status: TERMINATED